Bimagrumab is a human monoclonal antibody first developed by Novartis and currently by Eli Lilly to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B.
Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half-life and is administered once a month. From Wikipedia
